Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results
Initial clinical results from Phase 2 SUMMIT trial in NonAdvSM along with updated data from Phase 2 APEX trial in...
Brain
Theriva™ Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results
- Initiated dosing at U.S. sites for VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for...
Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
Announced Positive Topline Results from CT1812 Phase 2 SEQUEL Study in Mild-to-Moderate Alzheimer’s Disease Commenced Recruitment for 540-patient Phase 2...
Medicenna Appoints Dr. Arash Yavari as Chair of Development Advisory Committee
Development Advisory Committee strengthened with the expertise and leadership of Dr. YavariTORONTO and HOUSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) --...
New Study Finds That Masimo SedLine® Patient State Index (PSi) Has the Potential to Improve Brain Monitoring for Patients Sedated with Dexmedetomidine
Masimo PSi, a Processed EEG Parameter, “Better Captured” Changes in Brain State Compared to Other Assessment MethodsIRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ:...
Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms
New migraine data builds on prior clinical studies in depression Migraine trial results Migraine trial results Depression trial results Depression...
MBX Biosciences Announces U.S. FDA Clearance of IND Application for MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
Phase 1 trial initiation anticipated Q3 2023; Topline results expected in 2H 2024CARMEL, Ind., Aug. 07, 2023 (GLOBE NEWSWIRE) --...
Voyager Therapeutics Announces Appointment of Beth Shafer as Chief Business Officer
CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers...
Rhythm Pharmaceuticals Announces Pre-Marketing Early Access Authorization for Setmelanotide for Use in Patients with Hypothalamic Obesity in France
-- Reimbursed early access program allows for patients with hypothalamic obesity in France to receive setmelanotide treatment ---- Early access...
Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights
Reported promising interim data from Cohorts 1-4 in the Imagine-1 clinical trial for GM1 gangliosidosis (GM1); PBGM01 continued to have...
Helius Medical Technologies, Inc. Announces Participation of Montefiore Medical Center in its PoNS® Therapeutic Experience Program
Sixth Center of Excellence added in multi-center, company-sponsored, open label observational interventional trial to evaluate the impact of subjects’ adherence...
Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study
Interim safety data up to 28 months showed Dose 1 and 2 of PBGM01 were well tolerated and had a...
Tonix Pharmaceuticals Completes Clinical Phase of PREVAIL Proof-of-Concept Study of TNX-102 SL for the Treatment of Fibromyalgia-Type Long COVID
Topline Results Expected Third Quarter 2023 Long COVID Afflicts Approximately 19% of Patients Following COVID-191, and is Expected to be...
Gain Therapeutics Announces Acceptance of Late Breaking Abstract for Presentation at the International Congress of Parkinson’s Disease and Movement Disorders®
BETHESDA, Md., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX), a biotechnology company leading the discovery and...
Praxis Precision Medicines Announces Positive Results of EEG Analysis of PRAX-628 Phase 1 Study
Composite qEEG measure showed change from placebo after first dose of 5 mg Effect in the composite qEEG measured through...
Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Highlights
– First patient dosed in phase 1/2 trial of TNG462, a next-generation PRMT5 inhibitor for the treatment of MTAP-deleted tumors...
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
Postpartum depression (PPD) approval based on results from two Phase 3 clinical trials; in the SKYLARK Study treatment with ZURZUVAE...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO and SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology...
Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates
Completed single ascending dose (SAD) portion of Phase 1 trial evaluating OV329, a potential next-generation GABA-aminotransferase inhibitor Executed equity investment...
VoxNeuro Raises $3.4M to Accelerate Scaling Its Brain Performance Software Across US Clinics
VoxNeuro’s technology addresses the increased demand for cognitive health assessments with a simplified and objective software solution Financing to support...